European Urology Oncology

Slides:



Advertisements
Similar presentations
MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.
Advertisements

V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of MR/Ultrasound Fusion–Guided Biopsy With.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Volume 197, Issue 2, Pages S200-S207 (February 2017)
Volume 59, Issue 2, Pages (February 2011)
Volume 71, Issue 2, Pages (February 2017)
Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.
Volume 71, Issue 6, Pages (June 2017)
Volume 69, Issue 3, Pages (March 2016)
Volume 72, Issue 2, Pages (August 2017)
Algorithm for the laboratory diagnosis of androgen deficiency in the male. T, testosterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone;
Volume 56, Issue 6, Pages (December 2009)
Volume 69, Issue 2, Pages (February 2016)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Volume 67, Issue 3, Pages (March 2015)
European Urology Oncology
Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy  Darren J.
Volume 71, Issue 2, Pages (February 2017)
Prostate Cancer Epidemic in Sight?
Volume 61, Issue 3, Pages (March 2012)
Volume 72, Issue 3, Pages (September 2017)
Volume 186, Issue 4, Pages (October 2011)
Volume 66, Issue 1, Pages (July 2014)
Volume 69, Issue 3, Pages (March 2016)
European Urology Oncology
Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.
Volume 197, Issue 2, Pages S200-S207 (February 2017)
Volume 56, Issue 2, Pages (August 2009)
Volume 199, Issue 4, Pages e768-e769 (April 2018)
Volume 62, Issue 6, Pages (December 2012)
Volume 70, Issue 5, Pages (November 2016)
Volume 67, Issue 4, Pages (April 2015)
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions  Anwar R. Padhani, Jeffrey Weinreb, Andrew.
Volume 65, Issue 3, Pages (March 2014)
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Prostate Cancer Epidemic in Sight?
Volume 68, Issue 6, Pages (December 2015)
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 68, Issue 4, Pages (October 2015)
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.
Volume 65, Issue 4, Pages (April 2014)
Volume 68, Issue 6, Pages (December 2015)
Volume 66, Issue 3, Pages (September 2014)
European Urology Oncology
European Urology Oncology
European Urology Oncology
European Urology Oncology
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 75, Issue 4, Pages (April 2019)
Volume 73, Issue 1, Pages (January 2018)
The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance.
Volume 53, Issue 6, Pages (June 2008)
Volume 65, Issue 3, Pages (March 2014)
Volume 75, Issue 4, Pages (April 2019)
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review  Alexey Surov, Hans Jonas Meyer, Andreas.
European Urology Oncology
Volume 69, Issue 1, Pages (January 2016)
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
European Urology Oncology
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
European Urology Oncology
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
European Urology Oncology
European Urology Oncology
European Urology Oncology
Introduction European Urology Supplements
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

European Urology Oncology Complications and Adverse Events of Three Magnetic Resonance Imaging–based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial  Olivier Wegelin, Leonie Exterkate, Marloes van der Leest, Johannes C. Kelder, J.L.H. Ruud Bosch, Jelle O. Barentsz, Diederik M. Somford, Harm H.E. van Melick  European Urology Oncology  DOI: 10.1016/j.euo.2019.08.007 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 Flowchart of the study. COG-TB = cognitive registration TRUS targeted biopsy; CSR = cancer suspicious regions; FUS-TB = MRI-TRUS fusion targeted biopsy; IIEF-5 = International Index of Erectile Function; IPSS = International Prostate Symptom Score; mpMRI = multiparametric MRI; MRI = magnetic resonance imaging; MRI-TB = in-bore MRI targeted biopsy; PIRADS = Prostate Imaging Reporting and Data System; TRUS = transrectal ultrasound. European Urology Oncology DOI: (10.1016/j.euo.2019.08.007) Copyright © 2019 European Association of Urology Terms and Conditions